Radionuclides for Radioimmunotherapy: Criteria for Selection
Overview
Oncology
Authors
Affiliations
In developing and designing radioimmunotherapy, the selection of the isotope is a major factor. This selection depends on a number of criteria and parameters, affecting usefulness and feasibility. Usefulness is directly related to the radiological performance of the ionising radiation in relation to tissue and its morphology, with a major distinction between the effects of alpha and beta-particles (or rays). Usefulness is also directly related to the pharmacodynamic performance of the isotope-carrier (e.g. antibody) complex, where the proper choice of isotope radiodecay halflife is of major importance. Feasibility depends on availability of the components in the isotope-ligand-carrier complex, and also on convenience and safety aspects in the preparation and the handling of the materials as well as in their application in patients. A comparison is made between the various properties of alpha-emitting isotopes that have been proposed over a number of years, concluding that the combination 225Ac- 213Bi deserves serious further attention.
Chen X, Ji M, Fisher D, Wai C Inorg Chem. 2011; 38(23):5449-5452.
PMID: 21494420 PMC: 3074518. DOI: 10.1021/ic990135+.
Sharkey R, Goldenberg D Immunotherapy. 2011; 3(3):349-70.
PMID: 21395378 PMC: 3123828. DOI: 10.2217/imt.10.114.
Cancer radioimmunotherapy with alpha-emitting nuclides.
Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal J Eur J Nucl Med Mol Imaging. 2005; 32(5):601-14.
PMID: 15841373 DOI: 10.1007/s00259-005-1803-2.